Optimal modes and targets of gene therapy in transplantation

Dolca Thomas, Manikkam Suthanthiran

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Genetic modification strategies have the potential to improve outcome following cell/organ transplantation. A unique opportunity in transplantation is that gene therapies need not be restricted to in vivo approaches and that ex vivo genetic modification of cell and/or organs can be of value. Improvements in vector design, production, and delivery should enhance transfection efficiency and optimize gene expression. Herein, we discuss potential modes of gene therapy, focusing on viral, liposome, or naked DNA-based systems for gene delivery. We suggest gene therapy targets taking into consideration the essential constituents of anti-allograft repertory. In addition to strategies that may have salutary effects in mitigating the threat of acute rejection, we suggest genetic strategies for minimizing ischemia/reperfusion injury as well as for the perennial problem of progressive functional loss of the transplanted organ. Data from pre-clinical transplant models support the idea that gene therapy may improve allograft function and survival. We are optimistic that gene therapy will be of clinical value in the near future in the management of recipients of allografts; we believe that genetic strategies would be essential for successful breaching of the formidable challenge of xenotransplantation.

Original languageEnglish
Pages (from-to)161-175
Number of pages15
JournalImmunological Reviews
Volume196
DOIs
Publication statusPublished - 1 Dec 2003
Externally publishedYes

Fingerprint

Genetic Therapy
Transplantation
Allografts
Gene Transfer Techniques
Heterologous Transplantation
Cell Transplantation
Organ Transplantation
Reperfusion Injury
Liposomes
Transfection
Transplants
Gene Expression
DNA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Optimal modes and targets of gene therapy in transplantation. / Thomas, Dolca; Suthanthiran, Manikkam.

In: Immunological Reviews, Vol. 196, 01.12.2003, p. 161-175.

Research output: Contribution to journalReview article

@article{87ad3a72bfc349a3826acfc64c8f1d8e,
title = "Optimal modes and targets of gene therapy in transplantation",
abstract = "Genetic modification strategies have the potential to improve outcome following cell/organ transplantation. A unique opportunity in transplantation is that gene therapies need not be restricted to in vivo approaches and that ex vivo genetic modification of cell and/or organs can be of value. Improvements in vector design, production, and delivery should enhance transfection efficiency and optimize gene expression. Herein, we discuss potential modes of gene therapy, focusing on viral, liposome, or naked DNA-based systems for gene delivery. We suggest gene therapy targets taking into consideration the essential constituents of anti-allograft repertory. In addition to strategies that may have salutary effects in mitigating the threat of acute rejection, we suggest genetic strategies for minimizing ischemia/reperfusion injury as well as for the perennial problem of progressive functional loss of the transplanted organ. Data from pre-clinical transplant models support the idea that gene therapy may improve allograft function and survival. We are optimistic that gene therapy will be of clinical value in the near future in the management of recipients of allografts; we believe that genetic strategies would be essential for successful breaching of the formidable challenge of xenotransplantation.",
author = "Dolca Thomas and Manikkam Suthanthiran",
year = "2003",
month = "12",
day = "1",
doi = "10.1046/j.1600-065X.2003.00091.x",
language = "English",
volume = "196",
pages = "161--175",
journal = "Immunological Reviews",
issn = "0105-2896",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Optimal modes and targets of gene therapy in transplantation

AU - Thomas, Dolca

AU - Suthanthiran, Manikkam

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Genetic modification strategies have the potential to improve outcome following cell/organ transplantation. A unique opportunity in transplantation is that gene therapies need not be restricted to in vivo approaches and that ex vivo genetic modification of cell and/or organs can be of value. Improvements in vector design, production, and delivery should enhance transfection efficiency and optimize gene expression. Herein, we discuss potential modes of gene therapy, focusing on viral, liposome, or naked DNA-based systems for gene delivery. We suggest gene therapy targets taking into consideration the essential constituents of anti-allograft repertory. In addition to strategies that may have salutary effects in mitigating the threat of acute rejection, we suggest genetic strategies for minimizing ischemia/reperfusion injury as well as for the perennial problem of progressive functional loss of the transplanted organ. Data from pre-clinical transplant models support the idea that gene therapy may improve allograft function and survival. We are optimistic that gene therapy will be of clinical value in the near future in the management of recipients of allografts; we believe that genetic strategies would be essential for successful breaching of the formidable challenge of xenotransplantation.

AB - Genetic modification strategies have the potential to improve outcome following cell/organ transplantation. A unique opportunity in transplantation is that gene therapies need not be restricted to in vivo approaches and that ex vivo genetic modification of cell and/or organs can be of value. Improvements in vector design, production, and delivery should enhance transfection efficiency and optimize gene expression. Herein, we discuss potential modes of gene therapy, focusing on viral, liposome, or naked DNA-based systems for gene delivery. We suggest gene therapy targets taking into consideration the essential constituents of anti-allograft repertory. In addition to strategies that may have salutary effects in mitigating the threat of acute rejection, we suggest genetic strategies for minimizing ischemia/reperfusion injury as well as for the perennial problem of progressive functional loss of the transplanted organ. Data from pre-clinical transplant models support the idea that gene therapy may improve allograft function and survival. We are optimistic that gene therapy will be of clinical value in the near future in the management of recipients of allografts; we believe that genetic strategies would be essential for successful breaching of the formidable challenge of xenotransplantation.

UR - http://www.scopus.com/inward/record.url?scp=0344553376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344553376&partnerID=8YFLogxK

U2 - 10.1046/j.1600-065X.2003.00091.x

DO - 10.1046/j.1600-065X.2003.00091.x

M3 - Review article

VL - 196

SP - 161

EP - 175

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

ER -